A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)-China Extension Study

NCT05600309 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

94

Enrollment

INDUSTRY

Sponsor class

Conditions

Colorectal Cancer

Interventions

BIOLOGICAL: favezelimab/pembrolizumab
DRUG: regorafenib
DRUG: TAS-102

Sponsor

Merck Sharp & Dohme LLC